Core Insights - Tonghua Dongbao (600867.SH) reported a revenue of 1.373 billion yuan for the first half of 2025, representing a year-on-year growth of 85.6% [1] - The company achieved a net profit attributable to shareholders of 218 million yuan, marking a turnaround from a loss to profit year-on-year [1] - The non-recurring net profit was 221 million yuan, also indicating a year-on-year turnaround to profitability [1] - Basic earnings per share stood at 0.11 yuan [1]

Core Viewpoint - Tonghua Dongbao, a leading insulin manufacturer, reported significant growth in revenue and profit for the first half of 2025, driven by the rapid increase in sales of insulin analogs and the successful implementation of national insulin procurement policies [1][2][6] Financial Performance - The company achieved a revenue of 1.373 billion yuan, representing a year-on-year increase of 85.60% [1] - Net profit attributable to shareholders reached 218 million yuan, marking a turnaround from losses [1] - The second quarter revenue was 722 million yuan, showing a quarter-on-quarter growth of 10.82% [1] Product Growth - Sales of insulin analogs increased by over 200% year-on-year, with the Aspart series insulin sales surging by over 360% [1][2] - Insulin analogs now account for over 40% of the company's total revenue, indicating a significant shift in product structure [2] Market Expansion - The company has made substantial progress in hospital access, adding approximately 1,400, 3,000, and 5,000 hospitals for different insulin products [2] - The total signed volume for insulin products in the upcoming procurement cycle is approximately 45 million units, a significant increase from 26 million units in the previous cycle [1] R&D and Innovation - R&D expenditure reached 341 million yuan, a nearly 60% increase year-on-year, reflecting the company's commitment to innovation [3] - The company is advancing multiple innovative drug candidates in the endocrine metabolism field, including GLP-1 receptor agonists and dual-target inhibitors [3][4] International Market Development - Overseas revenue reached 110 million yuan, surpassing the total for the previous year [5] - The company is actively pursuing international market opportunities, with strategic collaborations in the U.S. and sales in emerging markets like Brazil and Russia [5][6] Long-term Growth Potential - The company is positioned for sustained growth due to the increasing market share from insulin procurement, ongoing product structure optimization, and the development of innovative drug pipelines [6] - The transition from a leading insulin manufacturer to an innovator in the endocrine field is anticipated to further enhance growth prospects [6]

Core Insights - Tonghua Dongbao reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 1.373 billion yuan, a year-on-year growth of 85.6%, and a net profit of 218 million yuan compared to a loss of 23 million yuan in the same period last year [1][2] Financial Performance - The company's revenue for the first half of 2025 was 1.373 billion yuan, marking an 85.6% increase year-on-year, primarily driven by a notable rise in sales of insulin analog products [1] - The net profit attributable to shareholders was 218 million yuan, a significant recovery from a loss of 23 million yuan in the previous year [1][2] - The net profit excluding non-recurring items was 221 million yuan, compared to a loss of 22.9 million yuan in the same period last year [1] Market Strategy and Growth - The company capitalized on the opportunities presented by the new round of centralized procurement, rapidly advancing the hospital access of its insulin series products to expand market coverage [2] - In 2024, the company achieved excellent results in the centralized procurement process, with a nearly 20 million unit increase in signed agreements compared to the first round of procurement [2] - The overseas market revenue reached 110 million yuan in the first half of 2025, reflecting a year-on-year growth of nearly 187% [2] Product Development and Collaborations - The company has established a strategic partnership with Jianyou Co., Ltd. to enter the U.S. insulin market and has met EU GMP standards for its human insulin raw material production facilities [3] - Several insulin products have received approval for sale in international markets, including Uzbekistan and Nicaragua, with ongoing registration efforts in developing countries [3] - The company is advancing the registration and application process for its GLP-1 product, liraglutide, in 17 emerging markets, having already submitted registration documents in multiple countries [3] Future Planning - The company is proactively planning future production lines for new products and is systematically advancing the construction of its biopharmaceutical production base [3] - The new production line for aspart insulin has been approved and is now in production, while the construction of the production base for liraglutide/aspart insulin is in a usable state [3]

2025年1至6月份，通化东宝的营业收入构成为：制药行业占比98.59%，其他业务占比1.27%，房地产行 业占比0.14%。 每经AI快讯，通化东宝（SH 600867，收盘价：8.61元）8月25日晚间发布公告称，公司计提信用减值损 失-353.26万元，资产减值损失2669.07万元，合计2315.81万元，减少公司2025年半年度利润总额2315.81 万元。 截至发稿，通化东宝市值为169亿元。 （记者 张喜威） 每经头条（nbdtoutiao）——A股成交连续8天破2万亿元，券商招聘也来了！行业巨头秋招"求才"，25个 岗位都有什么特点？ ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-052 二、本次计提资产减值准备的具体说明 （一）信用减值损失 通化东宝药业股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"）于2025年8月25日召开第十一届 董事会第十六次会议，审议通过了《关于计提资产减值准备的议案》，为了更加客观、 公正地反映公司财务状况和资产价值，根据《企业会计准则》等相关规定，结合企业实 际经营情况和资产现状，对2025年半年度相关资产进行了减值迹象的识别，对于其中已 出现减值迹象的进行了减值测试，并根据测试结果计提相关资产减值准备，现将具体情 况公告如下： 一、本次计提资产减值准备情况概述 公司根据《企业会计准则第 8 号——资产减值》《企业会计准则第 22 号——金融工 具确认和计量》等相关规定以及公司的实际业务情况，对公司 2025年半年度合并范围内 相关资产进行减值测试，根据测试结果，公司部分资产存在减值的情形，计提各项资产 减值损失2,315. ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-053 会议召开时间：2025 年 10 月 9 日 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 24 日至 9 月 30 日 16:00 前登录上证路演中心网 站首页点击"提问预征集"栏目或通过公司邮箱（thdb600867@thdb.com）进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 通化东宝药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 26 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 10 月 9 日 14:00-15:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 通化东宝药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本 ...

(一) 提前离任的基本情况 证券代码：600867 证券简称：通化东宝 公告编号：2025-051 通化东宝药业股份有限公司 关于总经理辞职暨新任公司总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）董事会近 日收到总经理冷春生先生递交的书面辞职报告，冷春生先生因工作安排调整，基 于参股公司君合盟生物制药（杭州）有限公司的发展需要，申请辞去公司总经理 的职务。辞职后，冷春生先生继续担任公司副董事长职务并担任董事会战略委员 会、薪酬与考核委员会、提名委员会委员和审计委员会委员职务。同时公司决定， 聘任冷春生先生为公司首席科学顾问。 一、总经理离任情况 | 姓名 | 离任职务 | 离任时间 | 原定任期 | | 是否继 续在上 | | 是否存 在未履 行完毕 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 到期日 | 离任原因 | 市公司 及其控 | 具体职务（如适 用） | ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-050 通化东宝药业股份有限公司 第十一届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）第十一届 董事会第十六次会议，于 2025 年 8 月 25 日在公司会议室以现场结合通讯方式召 开，会议通知于 2025 年 8 月 15 日，以书面、电子邮件等形式发出。本次会议应 参加会议董事 9 人，实际出席会议董事 9 人，会议由董事长李佳鸿先生主持，监 事及高级管理人员列席了会议。会议符合《公司法》和《公司章程》的有关规定， 所作决议合法有效。会议审议并通过了如下决议： 二、董事会会议审议情况 （一）审议通过了《关于聘任公司总经理的议案》； 冷春生先生因工作安排调整，辞去公司总经理职务，聘任李佳鸿先生为公司 总经理。 任期自本次董事会审议通过之日起至第十一届董事会任期届满时止。 具体内容详见公司 2025 年 8 月 26 日在中国证券报、上海证券报及上海 ...

公司代码：600867 公司简称：通化东宝 通化东宝药业股份有限公司 2025 年半年度报告 通化东宝药业股份有限公司2025 年半年度报告 四、 公司负责人李佳鸿、主管会计工作负责人迟军玉及会计机构负责人（会计主管人员）王熠 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 1 / 183 通化东宝药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 ...

Core Viewpoint - The company announced the resignation of its general manager, Leng Chunsheng, due to work arrangement adjustments and the needs of its affiliated company, Junhe Alliance Biopharmaceuticals [1] Group 1 - Leng Chunsheng will continue to serve as the vice chairman of the company and has been appointed as the chief scientific advisor after his resignation [1] - The board of directors has approved the appointment of Li Jiahong as the new general manager, with a term lasting until the end of the current board's tenure [1]